← All trials
NCT03578341
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2018
- Primary completion
- Jun 30, 2019
- Completion date
- Jul 31, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 90
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Instituto Nacional de Perinatologia Isidro Espinosa de los ReyesLead sponsor
- Instituto Nacional de Perinatologia Isidro Espinosa de los ReyesReponsible party - principal investigator
- Instituto Nacional de Perinatologia Isidro Espinosa de los ReyesStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.